 | Up a level |
Journal Article
Bos, M., Gardizi, M., Heukamp, L. C., Merkelbach-Bruse, S., Schildhaus, H. -U., Scheffler, M., Nogova, L., Mattonet, C., Serke, M., Randerath, W. J., Gerigk, U., Bruemmendorf, T. H., Krueger, S., Panse, J., Kaminski, B., Reiser, M., Buettner, R. and Wolf, J. (2014). The Network Genomic Medicine: A prospective comprehensive molecular screening network for implementation of personalized lung cancer therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262
Bos, M., Gardizi, M., Heukamp, L. C., Schildhaus, H. -U., Merkelbach-Bruse, S., Nogova, L., Scheffler, M., Serke, M., Schulz, H., Krueger, S., Bruemmendorf, T. H., Panse, J., Schmitz, S., Gerigk, U., Randerath, W. J., Ko, Y. D., Kambartel, K., Huenerlituerkoglu, A. -N., Buettner, R. and Wolf, J. (2014). A retrospective analysis of overall survival of ALK translocation - and of EGFR mutation positive NSCLC patients treated with and without personalized therapy. Oncol. Res. Treat., 37. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262
Eisert, A., Scheffler, M., Michels, S., Schultheis, A., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y. -D, Gerigk, U., Heukamp, L. C., Buettner, R. and Wolf, J. (2014). Genetic variability and clinical presentation of patients with non-small cell lung cancer (NSCLC) harboring MET-amplifications. Oncol. Res. Treat., 37. S. 8 - 9. BASEL: KARGER. ISSN 2296-5262
Eisert, A. K., Scheffler, M., Michels, S., Schultheis, A., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y., Gerigk, U., Geist, T., Heukamp, L. C., Buettner, R. and Wolf, J. (2014). GENETIC VARIABILITY AND CLINICAL PRESENTATION OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MET-AMPLIFICATIONS. Ann. Oncol., 25. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Heukamp, L. C. and Buettner, R. (2013). Genomic analysis of small cell lung cancer - new therapeutic options? Onkologe, 19 (11). S. 958 - 962. NEW YORK: SPRINGER. ISSN 1433-0415
Rabenhorst, A., Leja, S., Florin, A., Foerster, A., Heukamp, L. C., Ullrich, R. T., Willenborg, S., Eming, S., Buettner, R. and Hartmann, K. (2015). Mast cell-derived vascular endothelial growth factor contributes to tumor growth. J. Invest. Dermatol., 135. S. S19 - 1. NEW YORK: NATURE PUBLISHING GROUP. ISSN 1523-1747
Rabenhorst, A., Leja, S., Florin, A., Heukamp, L. C., Ullrich, R. T., Foerster, A., Roers, A., Buettner, R. and Hartmann, K. (2015). Contribution of mast cell-derived VEGF to tumor growth. Exp. Dermatol., 24 (3). S. E33 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625
Rabenhorst, A., Leja, S., Florin, A., Heukamp, L. C., Ullrich, R. T., Foerster, A., Roers, A., Buettner, R. and Hartmann, K. (2015). Contribution of mast cell-derived VEGF to tumor growth. Exp. Dermatol., 24 (3). S. E33 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625
Riedel, R., Plenker, D., Michels, S., Nogova, L., Abdulla, D., Scheffler, M., Fischer, R., Brandes, V., Heukamp, L. C., Scheel, A. H., Buettner, R., Sos, M. L. and Wolf, J. (2017). KIF5B-MET fusion genes are novel targets in NSCLC and show sensitivity to MET inhibition with crizotinib. Oncol. Res. Treat., 40. S. 173 - 174. BASEL: KARGER. ISSN 2296-5262
Scheel, A. H., Dietel, M., Heukamp, L. C., Joehrens, K., Kirchner, T., Reu, S., Rueschoff, J., Schildhaus, H. U., Schirmacher, P., Tiemann, M., Warth, A., Weichert, W., Fischer, R. N., Wolf, J. and Buettner, R. (2016). Predictive PD-L1 immunohistochemistry for non-small cell lung cancer. Current state of the art and experiences of the first German harmonization study. Pathologe, 37 (6). S. 557 - 568. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963
Scheffler, M., Gardizi, M., Bos, M., Koenig, K., Michels, S., Fassunke, J., Heydt, C., Kuenstlinger, H., Ihle, M. A., Ueckeroth, F., Albus, K., Serke, M., Gerigk, U., Schulte, W., Toepelt, K., Nogova, L., Zander, T., Engel-Riedel, W., Stoelben, E., Ko, Y. -D., Randerath, W. J., Kaminsky, B., Panse, J., Becker, C., Hellmich, M., Merkelbach-Bruse, S., Buettner, R., Heukamp, L. C. and Wolf, J. (2014). Genetic heterogeneity and lack of prognostic impact of patients with non-small cell lung cancer (NSCLC) harboring PIK3CA mutation. Oncol. Res. Treat., 37. S. 65 - 66. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Michels, S., Gardizi, M., Koenig, K., Merkelbach-Bruse, S., Stamm, K., Heukamp, L. C., Buettner, R. and Wolf, J. (2014). DDR2 mutations in non-small cell lung cancer (NSCLC): clinical, histological and genetic characteristics. Oncol. Res. Treat., 37. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262
Scheffler, M., Schultheis, A., Michels, S., Teixido, C., Hartmann, W., Merkelbach-Bruse, S., Sebastian, M., Serke, M., Kropf-Sanchen, C., Wittersheim, M., Puetz, K., Binot, E., Schildhaus, H. -U., Heukamp, L. C., Rosell, R., Buettner, R. and Wolf, J. (2014). ROS1 rearrangement in non-small cell lung cancer (NSCLC): Prognostic and predicitve impact and genetic variability. Oncol. Res. Treat., 37. S. 66 - 67. BASEL: KARGER. ISSN 2296-5262
Schulte, J. H., Schulte, S., Heukamp, L. C., Astrahantseff, K., Stephan, H., Fischer, M., Schramm, A. and Eggert, A. (2013). Targeted Therapy for Neuroblastoma: ALK Inhibitors. Klinische Padiatr., 225 (6). S. 303 - 309. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1439-3824
Theurich, S., Schlaak, M., Steguweit, H., Heukamp, L. C., Wennhold, K., Kurschat, P., Rabenhorst, A., Hartmann, K., Shimabukuro-Vornhagen, A., Schloesser, H., Holtick, U., Hallek, M., Stadler, R. and von Bergwelt-Baildon, M. (2014). Tumor infiltrating B-cells in primary cutaneous T-cell lymphoma correlate with disease progression and might represent a novel target for immunotherapy. Exp. Dermatol., 23 (3). S. E25 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625
Theurich, S., Schlaak, M., Steguweit, H., Heukamp, L. C., Wennhold, K., Kurschat, P., Shimabukuro-Vornhagen, A., Schloesser, H., Holtick, U., Hallek, M., Stadler, R. and von Bergwelt-Baildon, M. (2014). Tumor infiltrating B-cells in primary cutaneous T-cell lymphoma correlate with disease progression and might represent a novel target for immunotherapy. Oncol. Res. Treat., 37. S. 31 - 32. BASEL: KARGER. ISSN 2296-5262
Thunnissen, E., Lissenberg-Witte, B., I, van den Heuvel, M. M., Monkhorst, K., Skov, B. G., Sorensen, J. B., Mellemgaard, A., Dingemans, A. M. C., Speel, E. J. M., de Langen, A. J., Hashemi, S. M. S., Bahce, I, van der Drift, M. A., Looijen-Salamon, M. G., Gosney, J., Postmus, P. E., Samii, S. M. S., Duplaquet, F., Weynand, B., Durando, X., Penault-Llorca, F., Finn, S., Grady, A. O., Oz, B., Akyurek, N., Buettner, R., Wolf, J., Bubendorf, L., Duin, S., Marondel, I, Heukamp, L. C., Timens, W., Schuuring, E. M. D., Pauwels, P. and Smit, E. F. (2019). ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. Lung Cancer, 138. S. 13 - 19. CLARE: ELSEVIER IRELAND LTD. ISSN 1872-8332
Vollbrecht, C., Koenig, K., Heukamp, L. C., Peifer, M., Buettner, R., Odenthal, M. and Schweighofer, C. D. (2014). Detection of hot spot and pathway related variants in chronic lymphocytic leukemia by multiplexed amplicon sequencing. Eur. J. Cancer, 50. S. S145 - 1. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Vollbrecht, C., Mairinger, F. D., Schweighofer, C. D., Heukamp, L. C., Merkelbach-Bruse, S., Buettner, R. and Odenthal, M. (2014). Testing cancer related gene panels for high throughput parallel sequencing. Eur. J. Cancer, 50. S. S145 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
Volz, C., Zaplatina, A., Siobal, M., Chatterjee, S., Schoettle, J., Meder, L., Florin, A., Koker, M., Buettner, R., Miao, H., Wang, B., Hallek, M., Acker-Palmer, A. S., Heukamp, L. C., Thomas, R. K. and Ullrich, R. (2016). Anti angiogenic treatment induces tumor cell invasion and metastasis via EphA2 signaling in NSCLC. Oncol. Res. Treat., 39. S. 88 - 89. BASEL: KARGER. ISSN 2296-5262
Weichert, W., Bartels, S., Braicu, I., Christinat, Y., Demes, M., Endris, V., Herold, S., Heukamp, L. C., Hummel, M., Lehmann, U., Merkelbach-Bruse, S., Pfarr, N., Rad, R., Sehouli, J., Siemanowski, J., Stenzinger, A., von Schwarzenberg, K., Vollbrecht, C., Wild, P. J. and Zocholl, D. (2022). High concordance of different molecular assays in the determination of HRD associated GIS in high grade epithelial ovarian cancer. Ann. Oncol., 33 (7). S. S808 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041